Lightlake Therapeutics Inc. to Conduct Phase II Testing of New Bulimia Nervosa Treatment at King's College London

Published: Oct 05, 2011

LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company” or “Lightlake”), an early stage biopharmaceutical company using its expertise of opioid antagonists to develop modern addiction treatments, announced today that it will conduct Phase II trials at King’s College London on an opioid antagonist-based nasal spray treatment for Bulimia Nervosa.

Back to news